Retrospective Probability of Success (PoS) answers “what usually happens across programs.” Apotek Signal answers “what is likely to happen for this asset.” Key Takeaways Apotek Signal quantifies clinical risk at the asset level :  It estimates the probability that a specific trio of drug–target–indication will succeed at a given clinical phase. Phase-aware by design : Separate models for clinical trial phase I, II, and III reflect how decision criteria change across developme

How optimizing leads early can foresee risks, ensure safety and developability, and protect intellectual properties

Translating AI-powered research into real-world cancer impact Apotek Joins NSF I-Corps Spark Special Cohort on AI/ML and Cancer Care Taipei | [November 12, 2025] — Vizuro is proud to announce that our Apotek platform  has been selected for the National Science Foundation (NSF) I-Corps Spark Cohort , beginning November 13, 2025 . This specialized program focuses on AI/ML-powered innovations in cancer research and care , empowering teams to translate cutting-edge science into

Partnership with Professor Woei-Jer Chuang of NCKU to explore AI-powered discovery in protein drug design Vizuro Apotek AI Drug Discovery Platform x Industry-Academia Collaboration with NCKU Taipei | [October 27, 2025] — Vizuro LLC, a leading innovator in multimodal causal AI and generative AI for drug discovery, today announced the signing of a Memorandum of Understanding (MOU) with Professor Woei-Jer Chuang, Ph.D., of the Department of Biochemistry and Molecular Biology, Na

Going beyond correlation to causality can reveal tremendous value and insights Key Takeaway Drug discovery has entered the era of big data. Every year, thousands of disease and normal samples are profiled — yet one critical bottleneck remains: identifying clinically meaningful target–marker gene pairs for new drug development . The core value of Apotek Path is for this purpose: Identify disease-relevant targets → Causal modeling reveals mechanistic gene interactions tailore

Why causal AI is becoming pharma’s next strategic differentiator — from target validation to clinical trials and real-world evidence. Visualizing the Ladder of Causation in Pharma: from seeing correlations, to doing interventions, to imagining counterfactuals — the foundation of causal AI in drug discovery. Introduction: The Limits of Correlation in Drug Discovery Drug discovery today generates unprecedented volumes of data. Omics, imaging, electronic health records, and real

Fig 1.  Adaptyv Bio “Protein Design Competition Round2” Competition Overview Protein binding remains one of the most challenging aspects...

Key Takeaways: The 2024 Nobel Prize in Chemistry was awarded for groundbreaking advancements in computational protein structure...